NCT03976752View on ClinicalTrials.gov

Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Considered for Future On-demand Peri-exposure HIV Prophylaxis Regimens

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

March 13, 2019

Primary Completion Date

September 20, 2019

Study Completion Date

September 20, 2019

Conditions
HIV/AIDS
Interventions
DRUG

Genvoya

"Genvoya is a fixed-dose combination anti-retroviral drug containing tenofovir alafenamide (TAF), emtricitabine (FTC), elvitegravir (EVG), and cobicistat.~At the second study visit, participants will be provided with a single dose of Genvoya, and instructed to take the dose at home with documentation by digital, time-stamped photo or video. At the third study visit, which will occur 24 hours after home dosing, participants will be given another single dose of Genvoya at the clinic."

Trial Locations (1)

30322

Hope Clinic, Atlanta

All Listed Sponsors
collaborator

Centers for Disease Control and Prevention

FED

lead

Emory University

OTHER

NCT03976752 - Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Considered for Future On-demand Peri-exposure HIV Prophylaxis Regimens | Biotech Hunter | Biotech Hunter